Harvard Bioscience Inc (nasdaq:HBIO) Share Price

Company Profile

Business description
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Contact
84 October Hill Road
Suite 10
HollistonMA01746
USA
T: +1 508 893-8999
E: [email protected]
https://www.harvardbioscience.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
339

Recommended

We see regulatory risk from both the US and Chinese governments.

Seth Goldstein, CFA | 25 October 2026

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,926.60	20.80	0.23%
CAC 40	7,842.18	59.36	0.76%
DAX 40	25,413.50	231.85	0.92%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,730.93	40.57	0.38%
HKSE	23,211.81	118.44	0.51%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,189.65	503.51	-0.80%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,809.90	14.70	0.17%
SSE Composite Index	3,697.52	7.04	0.19%